Episode Details

This episode breaks down the critical differences in securing reimbursement for In-Vitro Diagnostics (IVDs) between the European Union's national HTA bodies and the payer-driven system in the United States. We explore the specific requirements of key European agencies like Germany's G-BA and France's HAS and contrast them with the evidence demanded by CMS and private insurers in the U.S. Key Questions: • Is there a single reimbursement pathway for an IVD in the European Union? • Which national bodies decide if your IVD gets reimbursed in Germany and France? • How did the 2011 AMNOG act in Germany change evidentiary standards? • What are the core differences between the evidence required by EU HTA bodies and U.S. payers? • How does the role of CMS in the U.S. compare to that of a national HTA agency in Europe? • Why is demonstrating economic value just as important as clinical utility in the American market? • What are Local and National Coverage Determinations (LCDs/NCDs) in the U.S.? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.